Even highly rated products can fail miserably if they are designed for the wrong skin concern
Less ideal candidates: BMI 2730 (mild overweight) where the efficacy advantage may not justify the tolerability trade-off
Beyond simply providing medication, FuturHealth supports its clients with continuous personalized coaching, dietary advice, and regular health monitoring
The combination of GLP-1, GIP and/or GCG agonist actions with amylinthrough the incorporation of cagrisemaglutide or amicretinopens the door to the development of new multiagonists as treatments for obesity, type 2 diabetes, and possibly other chronic diseases
Think of it less like a quick fix and more like a long-term strategy for healthier, more resilient skin
When NOT to Increase Your Dose Do not increase because: You want faster results